💊 As the Draft Reports for the EU Pharma files are out, stakeholder-issue analysis will improve your chances to influence:
In December 2021, 412 organisations responded to the Public Consultation for the Revision of the EU general pharmaceuticals legislation. We analysed them using our Stakeholder-Issue analysis. Here are some takeaways:
1. Challenges Addressed
The most negative responses for the performance of the Pharma legislation are about medicine shortages. A significant 42% of respondents expressed concerns about the current legislation's ability to ensure consistent availability of medicines in the market, highlighting a pressing need for improvement in this area.
2. Areas of Success
On a positive note, a whopping 78% of respondents acknowledged the legislation's effectiveness in ensuring medicines of high quality, safety, and efficacy.
3. Future Focus - R&D Incentives
There are remarks about the future legislation as well. R&D incentives is the most striking topic as 35% of organisations persisted in addressing the issue in the upcoming revision.
Our Lobium Stakeholder-Issue Matrix can process thousands of position papers and determine if stakeholders are in favour or against issues raised. You can visualise coalitions through interactive graphs for better analysis.
Also check out our EP Amendment Analyser at www.lobium.ai, if you want to breeze through the pharma amendments at speed.
#EUAffairs #PharmaIndustry #HealthcareInnovation #MedicineAvailability #FutureOfHealthcare
#EUpharmalegislation
🤯